EUVIMEDEUVIMED entdecken
Fallbericht

Alirocumab in a high cardiovascular risk patient on hemodialysis with liver abnormalities

Periklis Dousdampanis, Stelios F Assimakopoulos, Ioulia Syrocosta, Ioannis Ntouvas, Kostas Gkouias, Konstantina Trigka

Hemodialysis International · 2020-07 · 24 (3)

DOI: 10.1111/hdi.12839 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Hemodialysis International, online erschienen am 12.05.2020. Verfasst von Periklis Dousdampanis und 5 weiteren Autor:innen. Beteiligte Einrichtung: Hemodialysis Unit Kyanos Stavros Patras, Achaia, Greece. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 12 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We present a male diabetic type 2 patient on hemodialysis (HD) with high cardiovascular (CVD) risk and hyperlipidemia. The patient was under cholesterol‐lowering therapy with statin and ezetimibe but he was obligated to discontinue due to chronic hepatitis C virus infection. Statins and ezetimibe may exert a potential hepatotoxic effect and for this reason, we attempted to find an alternative treatment to prevent CVD. Given that a potential hepatotoxic effect has not been reported for Abs SPCK9, we administered alirocumab 150 mg every 2 weeks for a total of 8 weeks. Low‐density lipoprotein levels have decreased and no side effects have been observed. In conclusion, alirocumab is a safe and efficient alternative therapy approach for HD patients with high CVD risk and liver abnormalities. We suggest that SPCK 9 inhibitors should be considered as a first line treatment for lowering cholesterol in this specific patient group.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AgedAntibodies, Monoclonal, HumanizedCardiovascular DiseasesHeart Disease Risk FactorsHumansLiver DiseasesMaleRenal DialysisRisk FactorsTreatment Outcome

Stichwörter der Autor:innen

AlirocumabHCVcardiovascular diseasehemodialysis

Substanzen

Antibodies, Monoclonal, Humanizedalirocumab

Autor:innen und Institutionen

  • Hemodialysis Unit Kyanos Stavros Patras, Achaia, Greece.
  • Division of Infectious Diseases, Department of Internal Medicine, Medical School, University of Patras, Patras, Greece.
  • Department of Internal Medicine, University Hospital of Patras, Patras, Greece.
  • Department of Vascular Surgery, University Hospital of Patras, Patras, Greece.

Zitieren

APA

Dousdampanis, P., Assimakopoulos, S. F., Syrocosta, I., Ntouvas, I., Gkouias, K., & Trigka, K. (2020). Alirocumab in a high cardiovascular risk patient on hemodialysis with liver abnormalities. Hemodialysis International, 24(3). https://doi.org/10.1111/hdi.12839

Vancouver

Dousdampanis P, Assimakopoulos SF, Syrocosta I, Ntouvas I, Gkouias K, Trigka K. Alirocumab in a high cardiovascular risk patient on hemodialysis with liver abnormalities. Hemodialysis International. 2020;24(3). doi:10.1111/hdi.12839

BibTeX
@article{Dousdampanis2020,
  author = {Dousdampanis, Periklis and Assimakopoulos, Stelios F and Syrocosta, Ioulia and Ntouvas, Ioannis and Gkouias, Kostas and Trigka, Konstantina},
  title = {Alirocumab in a high cardiovascular risk patient on hemodialysis with liver abnormalities},
  journal = {Hemodialysis International},
  year = {2020},
  volume = {24},
  number = {3},
  doi = {10.1111/hdi.12839}
}
Kostenlos starten →